Is Align Technology, Inc. (NASDAQ:ALGN) Potentially Undervalued?
Align Technology (NASDAQ:ALGN) appears to be trading at a reasonable price, slightly above its industry peers based on its P/E ratio. While the shares have seen recent volatility, the company's future looks promising with an expected profit growth of 78% over the next couple of years. Current shareholders and potential investors should consider other factors like management track record and balance sheet strength, especially given the stock's volatility.
Align Technology connects with dentists at Chicago Midwinter Meeting
Align Technology is currently participating in the Chicago Dental Society Midwinter Meeting. The company is engaging with general practitioner dentists to demonstrate how its solutions can simplify daily dental practices and foster growth for dental offices. Attendees can find more information and explore Align Technology's offerings at booth #1120.
Exact Sciences Q4 Earnings Match Estimates, Revenues Beat, Stock Up
Exact Sciences (EXAS) reported a net loss of 21 cents per share in Q4 2025, matching estimates, with revenues of $878.4 million beating the Zacks Consensus Estimate. Consolidated revenues for the full year reached $3.25 billion, an increase of 17.7%. The company saw strong revenue growth in both its Screening and Precision Oncology segments, though increased operating expenses led to a higher operating loss compared to the previous year.
DanceOne and Invisalign Partner to Bring Confidence to Dancers in Chicago, Fort Lauderdale and Atlanta
DanceOne, a leading producer of dance events, has partnered with Align Technology's Invisalign to bring confidence-boosting experiences to young dancers. The partnership will feature interactive activations at upcoming competitions in Chicago, Fort Lauderdale, and Atlanta, offering AI Digital Smart Mirrors, parent lounges, and oral health scans. Additionally, DanceOne and Invisalign will provide scholarships for dancers to attend future events, including the prestigious DancerPalooza.
PODD Stock Up on Q4 Earnings & Revenue Beat, Margins Rise
Insulet Corporation (PODD) reported strong fourth-quarter and full-year 2025 results, with adjusted EPS of $1.55 and revenues of $783.8 million, both surpassing Zacks Consensus Estimates. The company saw significant growth in Omnipod revenues, especially internationally, and expanded its gross and operating margins. Insulet also provided a positive outlook for full-year 2026 and the first quarter, projecting continued revenue growth.
PODD Stock Up on Q4 Earnings & Revenue Beat, Margins Rise
Insulet Corporation (PODD) reported strong fourth-quarter and full-year 2025 results, with adjusted EPS and revenues surpassing Zacks Consensus Estimates. The company saw significant growth in Omnipod revenues, particularly internationally, and expanded its gross and operating margins. Insulet also provided a positive outlook for full-year 2026 and robust guidance for the first quarter, reflecting continued momentum in its business.
Clear Aligners Market Set for Explosive Growth at 29.3% CAGR
The Clear Aligners Market is projected to grow at a Compound Annual Growth Rate (CAGR) of 29.3% from 2024 to 2031, driven by increasing demand for aesthetic orthodontic solutions, technological advancements, and adult adoption of discreet teeth straightening options. North America currently holds the largest market share at 54.6%, while Asia Pacific is anticipated to be the fastest-growing region. Key players like Align Technology, Danaher, and Institut Straumann AG are leading with continuous innovations.
Align Technology Earns Relative Strength Rating Upgrade; Hits Key Threshold
Align Technology (ALGN) has seen its Relative Strength (RS) Rating improve from 78 to 81, meeting the criteria for inclusion on watch lists focused on stocks with an 80 or higher RS Rating. This upgrade signals improving technical performance for the company. The proprietary RS Rating measures a stock's technical performance on a scale of 1 to 99, indicating its leadership in the market.
Labcorp Q4 Earnings Beat, Revenues Miss, Stock Down in Pre-Market
Labcorp (LH) reported Q4 2025 adjusted earnings per share of $4.07, surpassing the Zacks Consensus Estimate by 3% and rising 18% year-over-year. However, revenues of $3.52 billion missed estimates by 1%, causing the stock to decline slightly in pre-market trading. The company also provided its full-year 2026 revenue and adjusted EPS guidance, with both metrics aligning closely with Zacks Consensus Estimates.
Henry Schein (HSIC) Earnings Expected to Grow: Should You Buy?
Henry Schein (HSIC) is expected to report increased earnings and revenues for the quarter ended December 2025. While analysts project a 9.2% year-over-year EPS growth to $1.30 per share and revenues of $3.33 billion, the company's Zacks Earnings ESP of -0.77% combined with a Zacks Rank #3 makes it difficult to definitively predict an earnings beat. Despite a positive surprise history in past quarters, investors are advised to consider other factors beyond just earnings expectations.
Henry Schein One Integrates iTero Scanners
Henry Schein One has announced a direct data integration between Align Technology's iTero™ intraoral scanners and its practice management platforms: Dentrix, Dentrix Ascend, and Dentally. This collaboration aims to streamline digital scanning, diagnosis, and daily operations for dental practices globally by automatically importing iTero scans into patient records, eliminating manual steps. The integration enhances clinical confidence and operational efficiency, allowing dental teams to focus more on patient care and less on managing technology.
MDT Stock Up on Q3 Earnings and Revenue Beat, Margins Down
Medtronic plc (MDT) reported Q3 fiscal 2026 adjusted EPS of $1.36 and worldwide revenues of $9.02 billion, both surpassing Zacks Consensus Estimates. Despite this beat and organic revenue growth across its key segments, the company experienced contractions in gross and adjusted operating margins. Medtronic maintained its fiscal 2026 outlook, projecting organic revenue growth of 5.5% and adjusted EPS in the range of $5.62-$5.66.
ALCON-INC.-INVESTORS
This brief article announces Alcon's introduction of TOTAL30® Multifocal for Astigmatism. This new product is a one-month replacement contact lens designed for presbyopic patients who also have astigmatism, aiming to address critical vision needs for this demographic.
Henry Schein One Connects Align Technology’s iTero Scanners to Dentrix, Dentrix Ascend, and Dentally, Advancing a More Connected Global Standard of Care
Henry Schein One announced a direct data integration between Align Technology’s iTero intraoral scanners and its practice management platforms: Dentrix, Dentrix Ascend, and Dentally. This integration automates the import of iTero scans into patient records, enhancing clinical workflows and operational efficiency for dental practices globally. The collaboration aims to provide immediate diagnostic insights and streamline the move from scanning to patient care within a single, connected environment.
Henry Schein's Integration Enhances Dental Efficiency
Henry Schein's integration of iTero scanners with its dental platforms dramatically improves efficiency by automating the import of 3D scans into patient records, eliminating manual tasks. This integration enhances clinical decision-making by providing immediate diagnostic insights and supports global dental practices across multiple countries, expanding Henry Schein's reach. The use of high-resolution 3D imaging technology is expected to drive the digital transformation of the dental industry, improving patient care and treatment outcomes.
M&G PLC Buys New Shares in Align Technology, Inc. $ALGN
M&G PLC has acquired a new stake in Align Technology, Inc. (NASDAQ:ALGN) by purchasing 87,229 shares worth approximately $10.9 million during the third quarter. This investment makes M&G PLC the owner of 0.12% of the medical equipment provider's stock. Other institutional investors have also adjusted their positions in ALGN, which currently holds a "Hold" consensus rating from analysts with an average target price of $195.92.
Henry Schein One Connects Align Technology’s iTero™ Scanners to Dentrix, Dentrix Ascend, and Dentally, Advancing a More Connected Global Standard of Care
Henry Schein One has announced a new direct data integration connecting Align Technology's iTero™ intraoral scanners with its Dentrix, Dentrix Ascend, and Dentally practice management platforms. This integration streamlines workflows by automatically importing iTero scans into patient records, aiming to enhance diagnostic insights, operational efficiency, and care coordination for dental practices globally. The collaboration, which included Heartland Dental for its initial program, seeks to create a more connected standard of care in digital dentistry.
Dental scans flow into charts as Henry Schein One links iTero, Dentrix
Henry Schein One has announced the integration of Align Technology's iTero™ intraoral scanners with its practice management platforms: Dentrix, Dentrix Ascend, and Dentally. This new integration allows for the automatic import of iTero scans directly into patient records, enhancing clinical workflows, improving efficiency, and supporting better decision-making for dental professionals worldwide. The collaboration aims to create a more connected global standard of care in dentistry.
Envestnet Asset Management Inc. Buys 30,686 Shares of Align Technology, Inc. $ALGN
Envestnet Asset Management Inc. increased its stake in Align Technology, Inc. by 37.1%, purchasing 30,686 additional shares to now own 113,398 shares valued at approximately $14.2 million. This increase in holdings comes as Align Technology reported strong Q4 earnings, beating analyst estimates with $3.29 EPS and $1.05 billion in revenue. The company maintains an institutional ownership of 88.43% and a consensus analyst target price near $195.92.
Align Technology, Inc. (ALGN) Stock Analysis: Navigating Growth with 6.32% Potential Upside
Align Technology, Inc. (ALGN), known for Invisalign, shows a potential upside of 6.32% from its current price of $186.77, with an average target price of $198.57. The company demonstrates strong financial health with positive revenue growth of 5.30%, an EPS of 5.66, and significant free cash flow, despite not offering dividends. Technical indicators suggest the stock is oversold, potentially presenting a buying opportunity, although analyst ratings are mixed reflecting competitive industry challenges.
Bruker's Q4 Earnings Lag Estimates, Margins Contract, Stock Down
Bruker Corporation (BRKR) reported Q4 2025 adjusted earnings that missed analyst estimates by 9.2%, falling 22.4% year over year, despite revenues slightly beating expectations. The company experienced contracting gross and operating margins due to lower volume, unfavorable mix, tariffs, and currency headwinds. Bruker provided 2026 guidance, projecting revenue growth of 4% to 5% and adjusted EPS growth of 15% to 17%.
Transthyretin Amyloid Cardiomyopathy Market Set for Explosive Growth to US$ 64.09 Billion by 2033, Led by North America | Key Players - Pfizer Inc., Ionis Pharmaceuticals, Inc
The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) market, valued at US$ 4.32 Billion in 2024, is projected to reach US$ 64.09 Billion by 2033, growing at a CAGR of 35.3%. This explosive growth is driven by increasing disease awareness, improved diagnostics, an aging population, and advancements in targeted therapies like TTR stabilizers and RNAi therapies. North America leads the market, with key players including Pfizer Inc. (78% market share) and Alnylam Pharmaceuticals, Inc. (21% market share).
ResMed (RMD): Buy, Sell, or Hold Post Q4 Earnings?
ResMed (RMD) shares have underperformed the S&P 500 significantly over the last six months, prompting investors to reevaluate the stock. The company shows positive attributes including consistent currency revenue growth, strong long-term EPS growth, and an increasing free cash flow margin. Despite its recent drawdown, ResMed's stock trades at 21.1x forward P/E, leading to questions about its current buying opportunity.
Assessing Align Technology (ALGN) Valuation After Q4 Beat And 2026 Growth Guidance
Align Technology (ALGN) is under investor scrutiny after a strong Q4 performance, marked by record clear aligner case volumes and positive 2026 revenue growth guidance. Despite recent share price gains, the stock has experienced long-term declines, leading to a debate among investors about its current valuation. While one valuation narrative suggests a slight overvaluation, Simply Wall St's discounted cash flow model indicates the stock might be undervalued, proposing a fair value of US$222.20.
The Bull Case For Align Technology (ALGN) Could Change Following New Guidance, Buybacks, And Research Push
Align Technology (ALGN) announced fourth-quarter 2025 results, including sales of US$1,047.56 million and net income of US$135.76 million, alongside a 2026 revenue guidance of 3% to 4% growth worldwide. The company also completed a US$171.57 million share repurchase program and expanded its collaboration with the University of Bern for oral health research. These developments, particularly the solid revenue guidance and growing international case volumes, are expected to influence the investment narrative for Align Technology.
ING Groep NV Has $1.09 Million Stake in Align Technology, Inc. $ALGN
ING Groep NV increased its stake in Align Technology, Inc. by 166.9% in the third quarter, bringing its total holdings to 8,715 shares valued at $1.09 million. Other institutional investors have also adjusted their positions in the company, with 88.43% of the stock currently owned by institutional investors and hedge funds. Analysts have a "Hold" rating on Align Technology, with an average price target of $195.92, following the company's recent earnings beat.
DDD Partners LLC Takes Position in Align Technology, Inc. $ALGN
DDD Partners LLC initiated a new position in Align Technology (NASDAQ:ALGN) during Q3, acquiring 9,228 shares valued at approximately $1.156 million. Align Technology recently surpassed quarterly expectations with $3.29 EPS and $1.05 billion in revenue, leading multiple analysts to raise their price targets to the $200-$220 range. The company, known for its Invisalign system, has also seen other institutional investors adjust their holdings.
Align Technology Inc. Is Quietly Printing Money – But Is This Invisible Braces King Still Worth Your Cash?
Align Technology, the company behind Invisalign, is a major player in clear aligners, blending health, beauty, and tech. Despite market volatility and concerns about its high valuation and competition, the product remains a premium choice for consumers and is seen as a strategic "cop on dips" for investors aligned with its long-term potential in digital dentistry. The article explores the company's market position, technology, and financial considerations for investors.
Align Technology Inc. Is Quietly Printing Money – But Is This Invisible Braces King Still Worth Yo
Align Technology, known for its Invisalign clear aligners, is a multibillion-dollar company often in the spotlight due to its volatile stock performance. The article explores whether the company, which merges health, beauty, and tech, is still a worthwhile investment given its premium product, advanced digital dentistry technology, and significant competition. While the product remains a "game-changer" for consumers, the stock is considered high-risk with potential for good returns on dips for investors who can tolerate volatility.
Align’s Swiss Oral Health Study Puts Digital Tools And Growth Story To Test
Align Technology is collaborating with the University of Bern on Switzerland's first comprehensive Oral Health Study, utilizing Align's iTero Lumina digital scanners and mobile dental vans to collect real-time oral health data. This partnership aims to expand the use of Align's digital tools in public health, moving beyond its core orthodontic products and potentially reinforcing its market position against competitors. While the study could broaden Align's addressable market through new preventive care use cases, investors should consider the risk that it may not immediately translate into higher sales or could expose Align to pricing pressures in large-scale public health programs.
Envista Stock Rises Post Q4 Earnings & Revenue Beat, Gross Margin Down
Envista Holdings Corporation (NVST) reported strong Q4 2025 results, with adjusted EPS up 58.3% year over year and revenues increasing by 15%, both beating Zacks Consensus Estimates. Despite a contraction in gross margin, the company's operational profit significantly improved, and its shares rallied post-announcement. Envista remains optimistic about its core sales growth and adjusted EBITDA margins for 2026, benefiting from its diverse portfolio in specialty products and technologies.
HSBC upgrades Align Technology amid market decline
HSBC upgraded Align Technology (ALGN) from Hold to Buy, increasing its price target from $150 to $200, despite broader market declines. The upgrade is attributed to Align Technology's strong brand presence, R&D culture, and "green shoots" in Q4 adult aligner shipments. This positive outlook is expected to boost investor confidence and support the company's expansion in the digital dentistry market.
Angelalign Technology Inc. (6699.HK) Says a Preliminary European Court Ruling on Certain Software Features Will Have Minimal Impact on Users
Angelalign Technology Inc. announced that a preliminary ruling by a German court regarding its software features for clear aligners will have minimal impact on its users. The company plans to launch an upgraded feature, iPlan, for affected European users and is challenging the patent infringement claims by Align Technology Inc. Angelalign denies any infringement and is confident the injunction will be overturned.
PBH's Q3 Earnings Miss Estimates, Revenues Surpass, Stock Up
Prestige Consumer Healthcare Inc. (PBH) reported mixed results for its fiscal third quarter of 2026, with diluted EPS of $1.14 missing estimates but total revenues of $283.4 million surpassing expectations. The company's stock edged up 0.6% after the announcement. Despite beating revenue estimates, the company faced challenges with lower Eye & Ear Care category sales and narrowing operating margins, leading to a narrowed fiscal 2026 sales outlook.
Candriam S.C.A. Sells 9,163 Shares of Align Technology, Inc. $ALGN
Candriam S.C.A. reduced its stake in Align Technology (NASDAQ:ALGN) by 15.7%, selling 9,163 shares and retaining 49,263 shares valued at approximately $6.17 million. Despite mixed analyst ratings, with a consensus "Hold" and an average price target of $195.92, Align Technology recently surpassed quarterly earnings and revenue estimates. The company reported $3.29 EPS against an expected $2.99 and $1.05 billion in revenue against an estimated $1.03 billion, representing a 5.3% year-over-year revenue increase.
5 Must-Read Analyst Questions From Align Technology's Q4 Earnings Call
Align Technology's Q4 earnings call highlighted strong growth in clear aligner volumes, particularly in international markets and within dental service organizations (DSOs), leading to a positive market response. Analysts focused on understanding the drivers of this volume growth, future guidance assumptions, average selling price trends, and the margin impact of direct fabrication. The company addressed these concerns by crediting market stability, successful execution in DSOs, and product innovation, while also acknowledging potential short-term margin dilution from new technologies.
Savant Capital LLC Decreases Stock Holdings in Align Technology, Inc. $ALGN
Savant Capital LLC significantly reduced its stake in Align Technology (ALGN) by 60.4% in Q3, selling over 11,000 shares. Despite this, Align Technology surpassed quarterly earnings and revenue estimates, reporting strong year-over-year revenue growth. Institutional ownership of ALGN stock remains high at 88.43%, with analysts giving the stock an average "Hold" rating and a price target close to its current trading price.
Dental Impression Systems Market Size, Share | Forecast [2034]
The global dental impression systems market, valued at USD 1.85 billion in 2025, is projected to reach USD 3.30 billion by 2034, growing at a CAGR of 6.7%. This growth is driven by increasing demand for dental treatments, technological advancements, and a significant shift from traditional to digital impression systems. Key market players like Dentsply Sirona and Align Technology are focusing on innovation and strategic partnerships to capitalize on these opportunities.
Skylands Capital LLC Acquires 39,750 Shares of Align Technology, Inc. $ALGN
Skylands Capital LLC significantly increased its stake in Align Technology, Inc. (NASDAQ:ALGN) by purchasing an additional 39,750 shares, bringing its total ownership to 48,200 shares valued at $6.036 million. This move is part of a broader trend of institutional investors adjusting their positions in the medical equipment provider. Align Technology's stock has seen fluctuations, but analysts maintain a "Hold" rating with an average target price of $195.92, while the company recently exceeded earnings expectations.
Quest Diagnostics' Q4 Earnings & Revenues Beat Estimates, Stock Up
Quest Diagnostics (DGX) reported better-than-expected earnings and revenues for the fourth quarter of 2025, with adjusted EPS of $2.42 and revenues of $2.81 billion, both surpassing consensus estimates. The company's Diagnostic Information Services revenues saw a 7.3% increase, and volumes were up 8.5% year-over-year. Quest Diagnostics also provided a positive outlook for full-year 2026 revenues and adjusted EPS, contributing to a nearly 2% gain in pre-market trading for DGX shares.
Align Technology leaders drive confidence in action dialogue
Align Technology recently hosted an event featuring a discussion on "confidence in action" with Dr. Mitra Derakhshan, EVP and Chief Clinical Officer, Global Treatment Planning and Clinical Services. She was joined by Kamal Bhandal, SVP of Global Invisalign Brand, Consumer & Americas Marketing, to share their insights on global treatment strategies. This dialogue aimed to foster confidence and share perspectives within the company's leadership.
Allianz Asset Management GmbH Sells 412,873 Shares of Align Technology, Inc. $ALGN
Allianz Asset Management GmbH significantly reduced its stake in Align Technology (ALGN) by selling 412,873 shares, an 80.8% decrease, valuing its remaining holdings at $12.25 million. This institutional selling occurred despite Align Technology beating Q4 earnings estimates with strong revenue and analyst price target increases. The company's stock performance shows a 50-day moving average of $163.26 and a 200-day moving average of $148.06, with a market cap of $13.46 billion.
Eli Lilly To Rally More Than 21%? Here Are 10 Top Analyst Forecasts For Monday
This article compiles ten top Wall Street analyst forecasts for Monday, highlighting several companies including Eli Lilly, Roblox, Align Technology, Biogen, Hims & Hers Health, Fortinet, STAAR Surgical, Robinhood Markets, and Walmart. Analysts have updated price targets and ratings, with some upgrades and some downgrades. For instance, Deutsche Bank raised Eli Lilly's price target to $1,285, suggesting a potential rally of over 21%.
This Oracle Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Five major companies - Roblox, Align Technology, Timken Co, Oracle Corp, and Medtronic PLC - received analyst upgrades. Oracle Corp, in particular, saw its rating upgraded from Neutral to Buy by DA Davidson. These upgrades reflect changing outlooks from top Wall Street analysts on these respective stocks.
STAAR Surgical stock price target lowered to $19 by Stifel on China concerns
Stifel has lowered its price target for STAAR Surgical (NASDAQ:STAA) to $19 from $28, while maintaining a Hold rating due to ongoing uncertainty in the Chinese refractive market. The firm noted that despite STAAR's Implantable Collamer Lens gaining market share in China, procedure volumes remain soft. Stifel awaits signs of improvement in the Chinese market and management stability before adopting a more positive outlook.
ALGN Stock Upgraded by HSBC: Target Price Now $200 | ALGN Stock News
HSBC has upgraded Align Technology (ALGN) stock from "Hold" to "Buy," increasing its price target to $200, a 33.33% raise. This upgrade, alongside other recent analyst revisions, reflects growing confidence in the company's future performance. Align Technology, known for its Invisalign clear aligners, holds a dominant market share and continues to expand its patient base and product offerings like iTero intraoral scanners.
What Makes MSA Safety (MSA) an Investment Bet?
Sequoia Strategy, managed by Ruane, Cunniff LP, recently added MSA Safety Incorporated (NYSE:MSA) to its portfolio, highlighting the company's strong position as a leading manufacturer of premium workplace safety equipment. MSA Safety has a long history of innovation, capturing the top or second spot in most of its core product categories within a stable and attractive market. Despite MSA Safety's potential, the article suggests that some AI stocks might offer even higher returns in a shorter timeframe.
Do You Believe in the Long-Term Growth Potential of Align Technology (ALGN)?
Sequoia Strategy, managed by Ruane, Cunniff LP, recently added Align Technology, Inc. (NASDAQ: ALGN) to its portfolio. The investment firm believes in the long-term growth potential of the medical device company, known for its Invisalign system, despite its shares being down over the past year. Align Technology is highlighted for its strong financial position, global presence, and operating margins.
Align Technology stock upgraded to Buy at HSBC on 3D printing potential
HSBC upgraded Align Technology (NASDAQ:ALGN) from Hold to Buy, raising its price target to $200.00 from $150.00 due to strong Q4 2025 results and the potential of upcoming direct 3D printing technology. Align's shares have surged, and the company is expected to see improved revenue growth and adjusted EPS, with analysts also highlighting its undervalued status and aggressive share buybacks. Other analysts like Piper Sandler and Stifel also raised their price targets following the positive earnings report.
Jackson Square Partners LLC Cuts Stake in Align Technology, Inc. $ALGN
Jackson Square Partners LLC significantly reduced its stake in Align Technology (NASDAQ:ALGN) by 40.6% during the third quarter, selling 9,280 shares and retaining 13,556 shares valued at $1.697 million. This comes despite Align Technology beating Q4 earnings estimates with strong Invisalign volumes, though the company also reported declining gross and operating margins. Analysts maintain a mixed "Hold" consensus for ALGN, with an average price target of $195.92.
